Salvia BioElectronics has raised €53m ($60m) in a Series B funding round towards advancing its non-invasive approach to treating chronic migraine.
The Dutch startup’s MySalvia therapy for individuals with chronic migraine uses implants that target key nerves involved in migraine, aiming to reduce the frequency and intensity of migraine attacks.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MySalvia users can activate the therapy, wherein electrical pulses intended to restore balance and relieve symptoms, are delivered by the neuromodulation implant via control of an external wearable device.
More common in women than men, estimates suggest that chronic migraine affects 1-2% of the global population.
Salvia’s implantable neurostimulation system was granted breakthrough device designation by the US Food and Drug Administration (FDA) in 2020. In 2023, a 29-year-old Australian woman became the first patient to be treated as part of the clinical trial (NCT05868044) for the device. The patient reported improvement in the frequency and intensity of her headaches immediately following the treatment.
Salvia founder and CEO, Hubert Martens commented: “Chronic migraine is not ‘just a headache’.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“It is a debilitating neurological condition that forces people out of their social life, their work, and the life they want to live. Our mission is to restore their freedom.”
Martens added that the latest funding tranche, which brings Salvia’s funding to date to around $97m, will support its advancement towards regulatory approval and commercialisation, with the ultimate goal being to reach the millions of people affected by chronic migraine.
Other companies developing neuromodulation devices for migraine include Neurolief. In 2024, the company’s Relivion neuromodulation device was approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for at-home use in the acute treatment of migraine.
Neuromodulation is now accelerating towards real-world breakthroughs for other conditions including tinnitus, substance use disorder, Parkinson’s disease, and epilepsy.
According to a report by GlobalData, the overall global neurological devices market will reach a valuation of $20.9bn by 2033, up from $12.5bn in 2023.
Recent moves by some of medtech’s biggest players include Abbott’s launch of a “next-generation” delivery system in April 2025 for streamlining the electrode implantation process for its Proclaim DRG neurostimulation system, and the initiation of a pivotal trial investigating its deep brain stimulation system for treatment-resistant depression in March.
